Imatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 210-215, 2011.
Article
Dans Anglais
| WPRIM
| ID: wpr-182755
ABSTRACT
Imatinib mesylate, a selective inhibitor of BCR-ABL kinase activity, has demonstrated significant clinical efficacy in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It has become the standard of treatment for these diseases. Although the toxicity profile of imatinib is superior to that of interferon or other cytotoxic agents, some adverse events including edema, gastrointestinal toxicities and hematologic toxicities are commonly observed in the patients treated by imatinib. We present two cases of imatinib induced interstitial pneumonitis during the treatment of a chronic phase of CML.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Phosphotransferases
/
Pipérazines
/
Pyrimidines
/
Benzamides
/
Leucémie myéloïde chronique BCR-ABL positive
/
Interférons
/
Pneumopathies interstitielles
/
Méthanesulfonates
/
Cytotoxines
/
Tumeurs stromales gastro-intestinales
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Tuberculosis and Respiratory Diseases
Année:
2011
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS